CClinicalTrials.gg
Sign In
Status unknownNCT05617469Updated Nov 15, 2022

DLCS for Predicting Neoadjuvant Chemotherapy Response

An observational study in Gastric Cancer, CT Images and Deep Learning, sponsored by Zhejiang Cancer Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Zhejiang Cancer Hospital · Observational

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,100
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.

02

Conditions studied

  • Gastric Cancer
  • CT Images
  • Deep Learning
  • Neoadjuvant Chemotherapy
  • Tumor Regression Grade

Browse trials for

03

In context

Stomach Neoplasms

2,850 studies on the registry are indexed under Stomach Neoplasms; 863 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 274 across 670 observational studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Zhejiang Cancer Hospital is the lead sponsor of 271 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients with histologically confirmed GC/esophagogastric junction cancer (EGJC) who received NCT prior to surgical resection

Inclusion criteria

  1. patients with GC/EGJC confirmed by pathological examination; 2) patients who underwent D2 lymphadenectomy; 3) patients who received at least two cycles of preoperative chemotherapy; 4) patients with negative resection margins; and 5) patients with complete CT image data and clinical data.

Exclusion criteria

Exclusion Criteria:

  1. patients unable to undergo D2 radical gastrectomy after neoadjuvant therapy; and 2) patients with incomplete CT images and clinical data.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,100 participants (estimated)
Patient registry
No

Interventions

  • Otherdevelop and visualized a radio-clinical signatures from pretreatment oversampled CT images

    develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis

06

What researchers measure

Primary outcomes

  1. Tumor regression grade

    Tumor regression grade

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
    Hangzhou, Zhejiang 310022, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to the privacy of patients, the data related to patients cannot be available for public access but can be obtained from the corresponding author on reasonable request approved by the institutional review board of all enrolled centers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05617469
Lead sponsor
Zhejiang Cancer Hospital
Responsible party
Xiangdong Cheng (Professor, Zhejiang Cancer Hospital) — Principal investigator
First posted
Nov 15, 2022
Start date
Jul 1, 2022
Primary completion
Jan 30, 2023 (estimated)
Completion
Jul 31, 2023 (estimated)
Last update
Nov 15, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stomach Neoplasms→

Other studies from this sponsor

Zhejiang Cancer Hospital

Start the discussion